Alexandra Thiry

2.5k total citations
65 papers, 1.8k citations indexed

About

Alexandra Thiry is a scholar working on Psychiatry and Mental health, Sensory Systems and Infectious Diseases. According to data from OpenAlex, Alexandra Thiry has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Psychiatry and Mental health, 13 papers in Sensory Systems and 12 papers in Infectious Diseases. Recurrent topics in Alexandra Thiry's work include Migraine and Headache Studies (42 papers), Olfactory and Sensory Function Studies (13 papers) and HIV/AIDS drug development and treatment (11 papers). Alexandra Thiry is often cited by papers focused on Migraine and Headache Studies (42 papers), Olfactory and Sensory Function Studies (13 papers) and HIV/AIDS drug development and treatment (11 papers). Alexandra Thiry collaborates with scholars based in United States, United Kingdom and Germany. Alexandra Thiry's co-authors include Kathleen Squires, Richard J. Colonno, Peter J. Piliero, Steven Schnittman, Neil Parkin, Robert Croop, Ian Sanne, Richard B. Lipton, Rong Yang and Ronald E. Rose and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Alexandra Thiry

56 papers receiving 1.7k citations

Peers

Countries citing papers authored by Alexandra Thiry

Since Specialization

Citations

This map shows the geographic impact of Alexandra Thiry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Thiry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Thiry more than expected).

Fields of papers citing papers by Alexandra Thiry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Thiry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Thiry. The network helps show where Alexandra Thiry may publish in the future.

Co-authorship network of co-authors of Alexandra Thiry

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Thiry. A scholar is included among the top collaborators of Alexandra Thiry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Thiry. Alexandra Thiry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	3
2	Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	0
3	Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	2
4	A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications 2025 ·Cephalalgia ·Patricia Pozo‐Rosich, (unknown), Paweł Lisewski, Abdullah Nabi Aslan, (unknown), Alexandra Thiry, Lucy Abraham, Luz M. Ramirez, Robert J. Fountaine, Terence Fullerton	0
5	Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial 2025 ·Cephalalgia ·Messoud Ashina, Peter McAllister, Charly Gaul, (unknown), Luz M. Ramirez, (unknown), Alexandra Thiry, Lucy Abraham, Robert J. Fountaine, Terence Fullerton	0
6	A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine 2025 ·Headache The Journal of Head and Face Pain ·David Kudrow, Robert Croop, Alexandra Thiry, Richard Lipton	4
7	Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 ·Journal of Pain Research ·Richard B. Lipton, Alexandra Thiry, (unknown), Robert Croop	14
8	A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine 2024 ·Cephalalgia ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry, Meghan Lovegren, Gilbert L’Italien, Richard B. Lipton	22
9	Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States 2024 ·Journal of Pain Research ·Gary Berman, Alexandra Thiry, Robert Croop	3
10	Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials 2023 ·Cephalalgia ·Richard B. Lipton, Andrew Blumenfeld, (unknown), Robert Croop, Alexandra Thiry, Gilbert L’Italien, Beth Morris, Vladimir Coric, Peter J. Goadsby	26
11	Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370) 2021 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Robert Croop, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vlad Coric, (unknown)	4
12	Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics (5072) 2021 ·Neurology ·David Kudrow, Kathleen Mullin, Gary Berman, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop	2
13	Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study (5084) 2021 ·Neurology ·Ira Turner, Jelena Pavlović, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop	1
14	Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091) 2020 ·Neurology ·Jelena Pavlović, David W. Dodick, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
15	Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609) 2020 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
16	Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864) 2020 ·Neurology ·Gilbert L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, (unknown), Meghan Lovegren, (unknown), Vladimir Coric, Richard B. Lipton	1
17	Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients 2005 ·Clinical Infectious Diseases ·Joseph G. Jemsek, Eduardo Arathoon, M. Arlotti, (unknown), (unknown), Vadim Pokrovskiy, Alexandra Thiry, (unknown), (unknown), Mauro Giordano	92
18	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients 2005 ·Gastroenterology ·Ting‐Tsung Chang, Robert G. Gish, Stephanos J. Hadziyannis, Janusz Cianciara, Mario Rizzetto, Eugene R. Schiff, Giuseppe Pastore, Bruce R. Bacon, Thierry Poynard, Shobha Joshi, K. Klesczewski, Alexandra Thiry, Ronald E. Rose, Richard J. Colonno, R. Hindes	199
19	Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Kathleen Squires, Adriano Lazzarin, (unknown), William G. Powderly, Vadim Pokrovskiy, (unknown), Joseph G. Jemsek, Antonio Rivero, Willy Rozenbaum, Shannon Schrader, Michael Sension, Asda Vibhagool, Alexandra Thiry, Michael Giordano	238
20	Atazanavir plus saquinavir once daily: favorable effects on lipid profiles in patients failing prior protease inhibitor therapy (trial AI424-009) 2002 ·Journal of the American College of Cardiology ·David W. Haas, Carlos Zala, Shannon Schrader, Alexandra Thiry, Rachel T. McGovern, Steven Schnittman	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact